IQCH Activators are a unique set of chemical compounds that indirectly contribute to the functional activation of IQCH through distinct signaling pathways. Forskolin, by enhancing adenylyl cyclase activity and thereby increasing intracellular cAMP levels, activates protein kinase A (PKA), which may then phosphorylate substrates including or associated with IQCH, resulting in its enhanced activity. Similarly, Epigallocatechin gallate (EGCG), by inhibiting protein kinases, reduces competitive signaling, potentially allowing IQCH-associated pathways to be more active. The lipid-derived messenger Sphingosine-1-phosphate (S1P) operates through its specific G protein-coupled receptors to initiate signaling cascades that may culminate in the enhancement of IQCH function. Moreover, Thapsigargin and Cyclic ADP-ribose (cADPR) both act to modulate intracellular calcium levels, which can activate calcium-dependent signaling cascades, potentially enhancing the activity of IQCH.
Phorbol 12-myristate 13-acetate (PMA) acts as a PKC activator, influencing signaling pathways that could phosphorylate and enhance the activity of IQCH. LY294002 and Wortmannin, both PI3K inhibitors, shift the balance of intracellular signaling potentially in favor of IQCH activation. In contrast, SB203580 and U0126, inhibitors of p38 MAPK and MEK1/2 respectively, might indirectly support the increased activity of IQCH by dampening competing pathways. The addition of A23187 (Calcimycin), a calcium ionophore, introduces another layer of signaling complexity by raising intracellular calcium levels, which may augment the functional activity of IQCH. Lastly, Staurosporine, while being a general kinase inhibitor, could paradoxically favor the activation of IQCH pathways by alleviating inhibitory kinases that otherwise suppress IQCH-related processes. Collectively, these IQCH Activators showcasehow they individually target specific signaling mechanisms to collectively enhance the functional activity of IQCH, without the need for upregulation at the genetic level.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased cyclic AMP (cAMP) levels. Elevated cAMP activates PKA, which can phosphorylate proteins including IQCH, potentially enhancing its function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits various protein kinases, which may reduce competitive signaling and indirectly enhance the function of IQCH by favoring its associated pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P binds to its G protein-coupled receptors, initiating signaling cascades that could lead to the functional activation of IQCH through downstream effectors. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin increases intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which can activate calcium-dependent kinases and phosphatases, potentially enhancing IQCH activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate target proteins and influence signaling pathways involving IQCH. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, altering downstream signaling pathways such as AKT, which may indirectly enhance the functional activity of IQCH. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that modulates AKT signaling, potentially affecting the functional activity of IQCH in a similar manner to LY294002. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could shift signaling dynamics to favor pathways where IQCH functions are enhanced. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to reduced ERK pathway activity, potentially allowing for the activation of alternative pathways involving IQCH. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore, elevating intracellular calcium levels and possibly enhancing pathways that modulate IQCH activity. | ||||||